CTOs on the Move

BioVentrix

www.bioventrix.com

 
BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.bioventrix.com
  • 12647 Alcosta Boulevard Suite 400
    San Ramon, CA USA 94583
  • Phone: 925.830.1000

Executives

Name Title Contact Details

Funding

BioVentrix raised $21.7M on 05/01/2019

Similar Companies

Prudential Cleanroom Svc

Prudential Cleanroom Svc is a Sandston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zimmer MedizinSystems

Zimmer MedizinSystems is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Trice Medical

Trice Medical was founded to fundamentally improve orthopedic diagnostics. Trice has pioneered fully integrated camera-enabled technologies that provide a clinical solution that is optimized for the physicians office. Our mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system.

MY01

MY01 is a state-of-the-art medical device geared towards aiding in the detection of Compartment Syndrome (CS); a limb-threatening muscle condition that occurs within 48 hours following trauma. Currently, ACS is diagnosed based on subjective and unreliable outcomes like pain (known as 6 P`s), which when present cannot confirm the diagnosis in time for effective intervention. This leads to increased complications (muscle necrosis/amputation) and costs the US healthcare system more than $2.25 B annually. MY01 is capitalizing on a proven correlation between sustained increase in Intramuscular pressures and ACS for objective, early diagnosis. MY01 operationalizes muscular pressure monitoring into a simple, accurate single-use device. MY01. The simple solution to a dangerous problem.

JenaValve

JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.